New ovarian cancer drug tested - 'Nanotax' news article Kansan

"The University of Kansas Cancer Center began running a Phase I clinical trial of the anti-ovarian cancer drug Nanotax. Nanotax is a breakthrough drug because, unlike other anti-cancer drugs, it is water-soluble....The clinical trial at the University comes nearly 15 year after Nanotax was first conceived. It is one of three active clinical trials for ovarian cancer treatment in Kansas, and it’s the only one still recruiting patients. The trial is classified as Phase I because it tests the drug in a small group.




Decedue said he wasn’t allowed to give out numbers because the clinical trial was not finalized, but he offered an optimistic analysis.

“The only thing I can tell you so far is that we have not seen any adverse effects to the drug or the procedure,” Decedue said. “That’s as good as it gets in a Phase I trial.”"